Bariatric surgery after GLP 1 failure brings large two year weight loss in Cleveland Clinic study

A Cleveland Clinic study published on 3 November in the Annals of Surgery puts numbers on bariatric surgery after GLP 1 drug failure. Adults who stopped semaglutide or tirzepatide because of side effects, or who lost little weight on them, still lost roughly 14% to 36% of their body weight in the two years after an operation. The cohort is observational and the drug groups are small. It does not move either approved peptide on our board, but it gives doctors data on a question their patients now raise often.

What the Cleveland Clinic study measured

Ali Aminian, who directs the Bariatric and Metabolic Institute at Cleveland Clinic, led the analysis with seven coauthors. The peer reviewed paper draws on electronic health records and pharmacy dispensing data for adults with a body mass index of 35 or more who had a Roux-en-Y gastric bypass or a sleeve gastrectomy at Cleveland Clinic hospitals in Ohio from 2018 to 2024. Of 4,929 patients, 4,661 had never taken semaglutide or tirzepatide and formed the comparator group. Another 61 had stopped a drug because of side effects they could not tolerate, and 207 had stayed on one but lost too little weight. The main outcome was total body weight loss two years after the operation, estimated for each procedure and by diabetes status.

The drug phase had done little for either rescue group before surgery. The authors estimate that the intolerance group gained 1.4% of body weight over two years of medication exposure, while the inadequate response group lost 1.5%. Becker's Hospital Review reports that poor responders had lost about 2% of their weight or less within two years of starting, and that median weight at surgery was roughly 273 to 287 pounds across the groups. So these were not people who did well on an incretin and then chose an operation. They were people for whom the drugs, as used in routine care, did not deliver. Why response varies so much is still unclear, and our report on a GLP1R gene variant found that genes explain only a small part of it.

Gastric bypass outpaced sleeve after a weak drug response

Surgery produced weight loss in all three groups, but the size of the effect depended on the operation. In people who had quit a drug because of side effects, two year loss after gastric bypass was 27.9% without type 2 diabetes and 22.7% with it, while sleeve gastrectomy gave 20.1% and 21.6%. Those figures sit near the comparator group, who had never used the drugs and lost 33.3% and 28.7% after bypass and 23.6% and 19.9% after sleeve. The intolerance group holds only 61 patients, so each of its four estimates rests on few people and should be read as a rough guide. Even so, that group lost far more after surgery than it had on medication, where it recorded a small net gain.

In the inadequate response group, an adjusted analysis credited gastric bypass with 32.7% total body weight loss at two years, against 17.8% after sleeve gastrectomy.

The inadequate response group showed the widest gap between procedures. Gastric bypass produced 35.8% weight loss in people without diabetes and 27.4% in those with it, while sleeve gastrectomy produced 14.3% and 14.2%. In the inadequate response group, an adjusted analysis credited gastric bypass with 32.7% total body weight loss at two years, against 17.8% after sleeve gastrectomy. The authors conclude that bypass may offer greater benefit after a poor drug response, and they use the word potentially. The study reports an association and does not test why the sleeve did worse in this group. For a surgeon choosing between the two operations, that is a signal worth weighing, not yet a rule, and the comparator results show sleeve outcomes were lower across the board.

Limits of an observational surgical cohort

The design limits what the numbers can prove about bariatric surgery after GLP 1 failure. Patients were not randomized; they and their surgeons chose the operation, and people who reach surgery after a failed drug may differ in motivation, health and insurance from those who do not. All patients came from one health system in one state. Becker's Hospital Review lists the limits the researchers themselves flagged: the observational design, small medication groups, follow up of only two years, and no way to confirm how consistently patients took their drugs. The last point matters because a person who skipped doses or never reached a full maintenance dose may look like a nonresponder on paper. The authors also said, according to Becker's, that the findings do not mean surgery is the right next step for every patient.

Several facts a careful reader would want are missing from the summaries we reviewed. They do not split results between semaglutide and tirzepatide, give the doses patients reached, or report surgical complications, readmissions or nutrition problems for the drug groups. Nor do they say whether anyone restarted a GLP 1 drug after surgery, an approach already studied for weight regain after surgery. Weight beyond two years is unknown. HealthDay reported that two authors disclosed ties to the pharmaceutical industry. Dose choices also shape who stays on treatment at all: our report on semaglutide discontinuation after high dose starts found a higher risk of early stopping. Some of the intolerance group may have been people whose start went badly, which this paper cannot show.

What it means for semaglutide and tirzepatide

For the two drugs, nothing changes on the board. Semaglutide and tirzepatide stay approved, and the paper makes no claim that surgery beats them in people who respond. What it adds is evidence for a sequence of care. The abstract calls intolerance and inadequate weight loss common and says the next step after them is uncertain; this cohort suggests that failing a drug does not predict failing an operation. That makes bariatric surgery after GLP 1 failure a reasonable topic for referral talks rather than a last resort. Aminian put the point in a Cleveland Clinic statement: "Not losing weight with a GLP-1 medication doesn't mean a patient won't lose weight after bariatric surgery." GLP 1 intolerance, in this reading, is a reason to reassess rather than to stop treating obesity.

A firmer answer should come from a randomized test. Aminian sponsors NCT06803888, an open label Cleveland Clinic trial that assigns adults who qualify for surgery to bypass or sleeve, semaglutide, or tirzepatide, with percent weight loss at 52 weeks as the primary outcome. The registry entry says it is not meant to compare the two drugs with each other, and a published review lists its primary completion for July 2027. Meanwhile, stronger peptide candidates keep advancing, among them the triple agonist retatrutide in Phase 3 and amylin combinations such as CagriSema, now filed. Whether they shrink the pool of patients who end up needing surgery is an open question that no trial has yet answered. Readers can follow each molecule on our pipeline board.

Conclusion

This study does not move semaglutide or tirzepatide, which stay approved. It shows that bariatric surgery after GLP 1 failure was linked to large two year weight loss at one US center, with gastric bypass ahead of sleeve gastrectomy after a weak drug response. The groups are small and the design is observational, so the numbers guide questions rather than settle them. The randomized Cleveland Clinic trial due to finish its primary phase in 2027 is the next real checkpoint.